In the liver, FTO overexpression promotes lipogenesis and lipid droplet accumulation, but decreases CPT-1-mediated FAO through sterol regulatory element-binding protein-1c (SREBP1c), leading to increased lipid storage and nonalcoholic fatty liver diseases (NAFLD).69 The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.